A hallmark of chronic kidney disease is the retention of solutes that normally are eliminated by the kidneys. The current classification defines uremic toxins based on molecular weight and protein affinity. The retention of solutes is already detected in the early stages of the disease when patients are pauci-symptomatic or asymptomatic but the role of therapies to retard the loss of kidney function in patients with chronic kidney disease (e.g., modulators of the renin-angiotensin-aldosterone system, sodium-glucose cotransporter inhibitors) in reducing uremic toxins is poorly understood. Most of the research evaluating the impact of therapies to lower serum concentrations of those toxic compounds is carried out in patients with kidney failure already undergoing kidney replacement therapy. The removal of those molecules relies in physicochemical mass transfer phenomena, i.e., adsorption, diffusion, and convection. In the past 2 decades, the rise and broad adoption of blood purification strategies with enhanced convective properties, such as high-volume online hemodiafiltration and expanded hemodialysis, considerably amplified the ability to mechanically extract middle molecules (molecular weight >0.5 kDa) from the blood compartment. Nonetheless, the classification of uremic toxins has not evolved in parallel with dialysis advancements. Mounting evidence demonstrates the link between middle molecules with uremic symptoms, cardiovascular and mortality risks. An urgent need for updating the classification exists. Defining the causative relationship between specific solutes and specific clinical outcomes will promote the development of targeted therapies. In parallel, the inclusion of new pertinent dimensions to the classification like the influence of new dialysis membranes, sorbents, and intestinal chelators in the concentration of uremic toxins would improve the understanding of the pathogenesis of chronic kidney disease, setting the pace for future research in nephrology.

1.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.
2.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
3.
Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3(1):17088.
4.
Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins. 2018;10(1):33.
5.
Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol. 2011;6(6):1266–73.
6.
te Linde E, van Roij CJM, Meijers BKI, De Loor H, Kessels RPC, Wetzels JFM. Cognitive function and uremic toxins after kidney transplantation: an exploratory study. Kidney360. 2020;1(12):1398–406.
7.
Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis. 2010;17(6):469–79.
8.
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–43.
9.
Ganesan LL, O’Brien FJ, Sirich TL, Plummer NS, Sheth R, Fajardo C, et al. Association of plasma uremic solute levels with residual kidney function in children on peritoneal dialysis. Clin J Am Soc Nephrol. 2021;16(10):1531–8.
10.
Hu J-R, Myint L, Levey AS, Coresh J, Inker LA, Grams ME, et al. A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease. Kidney Int. 2022;101(2):369–78.
11.
Vanholder R, Argiles A, Jankowski J, European Uraemic Toxin Work Group EUTox. A history of uraemic toxicity and of the European uraemic toxin work group (EUTox). Clin Kidney J. 2021;14(6):1514–23.
12.
Rosner MH, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P, et al. Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol. 2021;16(12):1918–28.
13.
Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, et al. Plant-based diets to manage the risks and complications of chronic kidney disease. Nat Rev Nephrol. 2020;16(9):525–42.
14.
Salmean YA, Segal MS, Palii SP, Dahl WJ. Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients. J Ren Nutr. 2015;25(3):316–20.
15.
Black AP, Anjos JS, Cardozo L, Carmo FL, Dolenga CJ, Nakao LS, et al. Does low-protein diet influence the uremic toxin serum levels from the gut microbiota in nondialysis chronic kidney disease patients? J Ren Nutr. 2018;28(3):208–14.
16.
Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 2013;35(1–3):196–201.
17.
Takkavatakarn K, Puapatanakul P, Phannajit J, Sukkumme W, Chariyavilaskul P, Sitticharoenchai P, et al. Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia: a randomized controlled trial. Toxins. 2021;13(10):688.
18.
Laville SM, Massy ZA, Kamel S, Chillon JM, Choukroun G, Liabeuf S. Intestinal chelators, sorbants, and gut-derived uremic toxins. Toxins. 2021;13(2):91.
19.
Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11(4):559–67.
20.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26(7):1732–46.
21.
Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, et al. Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract. 2017;36(1):68–78.
22.
McGlothlin AE, Viele K. Bayesian hierarchical models. JAMA. 2018;320(22):2365–6.
23.
Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17(8):528–42.
24.
Liu J, Pan Y, Chen L, Qiao QY, Wang J, Pan LH, et al. Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: a 5-y prospective cohort study: aspirin and CVD outcomes in hemodialysis patients. Hemodial Int. 2016;20(4):548–57.
25.
De Vriese AS. Should statins Be banned from dialysis? J Am Soc Nephrol. 2017;28(6):1675–6.
26.
Adesso S, Paterniti I, Cuzzocrea S, Fujioka M, Autore G, Magnus T, et al. AST-120 reduces neuroinflammation induced by indoxyl sulfate in glial cells. J Clin Med. 2018;7(10):365.
27.
Lin Y-T, Wu P-H, Tsai Y-C, Hsu Y-L, Wang HY, Kuo M-C, et al. Indoxyl sulfate induces apoptosis through oxidative stress and mitogen-activated protein kinase signaling pathway inhibition in human astrocytes. J Clin Med. 2019;8(2):191.
28.
Karbowska M, Hermanowicz JM, Tankiewicz-Kwedlo A, Kalaska B, Kaminski TW, Nosek K, et al. Neurobehavioral effects of uremic toxin–indoxyl sulfate in the rat model. Sci Rep. 2020;10(1):9483.
29.
Lin Y-T, Wu P-H, Liang S-S, Mubanga M, Yang Y-H, Hsu Y-L, et al. Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis. Sci Rep. 2019;9(1):20388.
30.
Rosner MH, Husain-Syed F, Reis T, Ronco C, Vanholder R. Uremic Encephalopathy. Kidney Int. 2022;101(2):227–41.
31.
Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018;14(6):394–410.
32.
Reis T, Anwar S, Neves Fd Ad R, Ronco C. Disruptive technologies for hemodialysis: medium and high cutoff membranes. Is the future now? J Bras Nefrol. 2021;43(3):410–6.
33.
Kanda E, Muenz D, Bieber B, Cases A, Locatelli F, Port FK, et al. Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study. Clin Kidney J. 2021;14(5):1436–42.
34.
Kirsch AH, Lyko R, Nilsson L-G, Beck W, Amdahl M, Lechner P, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transpl. 2017;32(1):165–72.
35.
Leypoldt JK, Storr M, Agar BU, Boschetti-de-Fierro A, Bernardo AA, Kirsch AH, et al. Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration. Nephrol Dial Transpl. 2019;34(5):870–7.
36.
Reque J, Pérez Alba A, Panizo N, Sánchez-Canel JJ, Pascual MJ, Pons Prades R. Is expanded hemodialysis an option to online hemodiafiltration for small- and middle-sized molecules clearance? Blood Purif. 2019;47(1–3):126–31.
37.
Eiamcharoenying J, Takkavatakarn K, Chariyavilaskul P, Susantitaphong P, Eiam-Ong S, Tiranathanagul K. Comparative effectiveness between expanded hemodialysis (hemodialysis using a medium cut-off dialyzer) and mixed-dilution online hemodiafiltration using a high-flux dialyzer in removing middle-molecule uremic toxins. Blood Purif. 2022;51(11):923–31.
38.
Maduell F, Rodas L, Broseta JJ, Gómez M, Xipell Font M, Molina A, et al. High-permeability alternatives to current dialyzers performing both high-flux hemodialysis and postdilution online hemodiafiltration. Artif Organs. 2019;43(10):1014–21.
39.
Maduell F, Broseta JJ, Rodríguez-Espinosa D, Hermida-Lama E, Rodas LM, Gómez M, et al. Evaluation and comparison of polysulfone TS-UL and PMMA NF-U dialyzers versus expanded hemodialysis and postdilution hemodiafiltration. Artif Organs. 2021;45(9):E317–E323.
40.
García-Prieto A, Vega A, Linares T, Abad S, Macías N, Aragoncillo I, et al. Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration. Clin Kidney J. 2018;11(5):742–6.
41.
Maduell F, Rodas L, Broseta JJ, Gomez M, Xipell M, Guillen E, et al. Medium cut-off dialyzer versus eight hemodiafiltration dialyzers: comparison using a global removal score. Blood Purif. 2019;48(2):167–74.
42.
Hadad-Arrascue F, Nilsson L, Rivera AS, Bernardo AA, Cabezuelo Romero JB. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: a randomized mid-term clinical trial. Ther Apher Dial. 2021;26(1):3737–44.
43.
Ronco C. Backfiltration: a controversial issue in modern dialysis. Int J Artif Organs. 1988;11(2):69–74.
44.
Ronco C. Backfiltration in clinical dialysis: nature of the phenomenon, mechanisms and possible solutions. Int J Artif Organs. 1990;13(1):11–21.
45.
Rangel AV, Kim JC, Kaushik M, Garzotto F, Neri M, Cruz DN, et al. Backfiltration: past, present and future. In: Krick G, Ronco C, editors. Contributions to nephrology. Basel: KARGER; 2011. p. 35–45.
46.
Ronco C, Brendolan A, Feriani M, Milan M, Conz P, Lupi A, et al. A new scintigraphic method to characterize ultrafiltration in hollow fiber dialyzers. Kidney Int. 1992;41(5):1383–93.
47.
Ronco C, Orlandini G, Brendolan A, Lupi A, La Greca G. Enhancement of convective transport by internal filtration in a modified experimental hemodialyzer: technical note. Kidney Int. 1998;54(3):979–85.
48.
Ronco C, Brendolan A, Lupi A, Metry G, Levin NW. Effects of a reduced inner diameter of hollow fibers in hemodialyzers. Kidney Int. 2000;58(2):809–17.
49.
Fiore GB, Ronco C. Internal hemodiafiltration (iHDF): a possible option to expand hemodiafiltration therapy. Int J Artif Organs. 2004;27(5):420–3.
50.
Ronco C. The rise of expanded hemodialysis. Blood Purif. 2017;44(2):I–VIII.
51.
Lorenzin A, Neri M, Lupi A, Todesco M, Santimaria M, Alghisi A, et al. Quantification of internal filtration in hollow fiber hemodialyzers with medium cut-off membrane. Blood Purif. 2018;46(3):196–204.
52.
Lorenzin A, Golino G, de Cal M, Pajarin G, Savastano S, Lupi A, et al. Flow dynamic analysis by contrast-enhanced imaging techniques of medium cutoff membrane hemodialyzer. Blood Purif. 2021;51(2):138–46.
53.
Cardoso A, Branco C, Sant’Ana M, Costa C, Silva B, Fonseca J, et al. Hypoalbuminaemia and one-year mortality in haemodialysis patients with heart failure: a cohort analysis. J Clin Med. 2021;10(19):4518.
54.
Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, et al. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS ONE. 2018;13(1):e0190410.
55.
MacLaughlin HL, Friedman AN, Ikizler TA. Nutrition in kidney disease: core curriculum 2022. Am J Kidney Dis. 2022;79(3):437–49.
56.
Maduell F, Broseta JJ, Rodríguez-Espinosa D, del Risco J, Rodas LM, Arias-Guillén M, et al. Comparison of four medium cut-off dialyzers. Clin Kidney J. 2022;15(12):2292–9.
57.
Canaud B, Davenport A. The rationale and clinical potential of on-line hemodiafiltration as renal replacement therapy. Semin Dial. 2022;35(5):380–4.
58.
Canaud B, Vienken J, Ash S, Ward RA, Kidney Health Initiative HDF Workgroup. Hemodiafiltration to address unmet medical needs ESKD patients. Clin J Am Soc Nephrol. 2018;13(9):1435–43.
59.
Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–8.
60.
Yamamoto S, Fuller DS, Komaba H, Nomura T, Massy ZA, Bieber B, et al. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. Clin Kidney J. 2021;14(4):1236–43.
61.
Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho Y, Wong M, et al. A tRial evaluating mid cut-off value membrane clearance of albumin and light chains in HemoDialysis patients: a safety device study. Blood Purif. 2020;49(4):468–78.
62.
Tiong MK, Krishnasamy R, Smith ER, Hutchison CA, Ryan EG, Pascoe EM, et al. Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodial Int. 2021;25(3):hdi.12924–32.
63.
Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A new series of sorbent devices for multiple clinical purposes: current evidence and future directions. Blood Purif. 2019;47(1–3):94–100.
64.
Nguyen Huu D, Dao Bui Quy Q, Nguyen Thi Thu H, Phan The C, Nguyen Thi Hong Q, Nguyen Duc L, et al. A combination of hemodialysis with hemoperfusion helped to reduce the cardiovascular-related mortality rate after a 3-year follow-up: a pilot study in vietnam. Blood Purif. 2021;50(1):65–72.
65.
Gu YH, Yang XH, Pan LH, Zhan XL, Guo LL, Jin HM. Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis. Int J Artif Organs. 2019;42(7):347–53.
66.
Rocchetti MT, Cosola C, di Bari I, Magnani S, Galleggiante V, Scandiffio L, et al. Efficacy of divinylbenzenic resin in removing indoxyl sulfate and P-cresol sulfate in hemodialysis patients: results from an in vitro study and an in vivo pilot trial (xuanro4-Nature 3.2). Toxins. 2020;12(3):170.
67.
Meyer TW, Sirich TL, Hostetter TH. Dialysis cannot be dosed. Semin Dial. 2011;24(5):471–9.
68.
Tiranathanagul K, Khemnark N, Takkavatakarn K, Limjariyakul M, Mahatanan N, Chariyavilaskul P, et al. Comparative efficacy between hemodialysis using super high-flux dialyzer with hemoperfusion and high-volume postdilution online hemodiafiltration in removing protein bound and middle molecule uremic toxins: a cross-over randomized controlled trial. Artif Organs. 2022;46(5):775–85.
69.
Yamamoto S, Sato M, Sato Y, Wakamatsu T, Takahashi Y, Iguchi A, et al. Adsorption of protein-bound uremic toxins through direct hemoperfusion with hexadecyl-immobilized cellulose beads in patients undergoing hemodialysis. Artif Organs. 2018;42(1):88–93.
70.
Molina P, Peiró J, Martínez-Gómez MA, Vizcaíno B, Esteller C, González-Moya M, et al. Combining diffusion, convection and absorption: a pilot study of polymethylmethacrylate versus polysulfone membranes in the removal of P-cresyl sulfate by postdilution on-line hemodiafiltration. Kidney Dial. 2021;1(2):121–34.
71.
Ronco C, Reis T. Continuous renal replacement therapy and extended indications. Semin Dial. 2021;34(6):550–60.
72.
Shi Y, Tian H, Wang Y, Shen Y, Zhu Q, Ding F. Improved dialysis removal of protein-bound uraemic toxins with a combined displacement and adsorption technique. Blood Purif. 2021;51(6):548–58.
73.
Eloot S, Vanholder R, Dequidt C, Van Biesen W. Removal of different classes of uremic toxins in APD vs CAPD: a randomized cross-over study. Perit Dial Int. 2015;35(4):436–42.
74.
Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and P-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol. 2008;3(1):85–90.
75.
Huang W-H, Hung C-C, Yang C-W, Huang J-Y. High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients. Ther Apher Dial. 2012;16(4):361–7.
76.
Pittman ZCL, John SG, McIntyre CW. Collection of daily patient reported outcomes is feasible and demonstrates differential patient experience in chronic kidney disease: iterative PROM use in CKD patients. Hemodial Int. 2017;21(2):265–73.
77.
Hall YN, Larive B, Painter P, Kaysen GA, Lindsay RM, Nissenson AR, et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: frequent hemodialysis network (FHN) randomized trials. Clin J Am Soc Nephrol. 2012;7(5):782–94.
78.
Capelli I, Pizza F, Ruggeri M, Gasperoni L, Carretta E, Donati G, et al. Time evolution of restless legs syndrome in haemodialysis patients. Clin Kidney J. 2021;14(1):341–7.
79.
Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord. 2002;17(5):1072–6.
80.
Alarcon JC, Bunch A, Ardila F, Zuñiga E, Vesga JI, Rivera A, et al. Impact of medium cut-off dialyzers on patient-reported outcomes: COREXH registry. Blood Purif. 2021;50(1):110–8.
81.
Belmouaz M, Bauwens M, Hauet T, Bossard V, Jamet P, Joly F, et al. Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transpl. 2020;35(2):328–35.
82.
Manconi M, Garcia-Borreguero D, Schormair B, Videnovic A, Berger K, Ferri R, et al. Restless legs syndrome. Nat Rev Dis Primers. 2021;7(1):80.
83.
Lim J-H, Park Y, Yook J-M, Choi S-Y, Jung H-Y, Choi J-Y, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep. 2020;10(1):7780.
84.
Lim J-H, Jeon Y, Yook J-M, Choi S-Y, Jung H-Y, Choi J-Y, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. Sci Rep. 2020;10(1):16062.
85.
Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients—a randomized controlled clinical trial. PLoS ONE. 2017;12(1):e0169024.
86.
Bolton S, Gair R, Nilsson L-G, Matthews M, Stewart L, McCullagh N. Clinical assessment of dialysis recovery time and symptom burden: impact of switching hemodialysis therapy mode. Patient Relat Outcome Meas. 2021;12:315–21.
87.
Ethier I, Nevis I, Suri RS. Quality of life and hemodynamic effects of switching from hemodialysis to hemodiafiltration: a Canadian controlled cohort study. Can J Kidney Health Dis. 2021;8:20543581211057717.
88.
Pecoits-Filho R, Larkin J, Poli-de-Figueiredo CE, Cuvello-Neto AL, Barra ABL, Gonçalves PB, et al. Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial. Nephrol Dial Transpl. 2021;36(6):1057–70.
89.
Lima JD, Guedes M, Rodrigues SD, Flórido ACS, Moreno-Amaral AN, Barra AB, et al. High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial. J Nephrol. 2022;35(5):1449–56.
90.
Maduell F, Broseta JJ, Rodríguez-Espinosa D, Hermida-Lama E, Cuadrado-Payán E, Rodas LM, et al. Efficacy and safety of the Clearum dialyzer. Artif Organs. 2021;45(10):1195–201.
91.
Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387–402.
92.
Li W-H, Yin Y-M, Chen H, Wang X-D, Yun H, Li H, et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine. 2017;96(12):e6160.
You do not currently have access to this content.